Share on StockTwits

Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments. The Basel, Switzerland-based pharmaceutical giant, which is the world’s biggest manufacturer of cancer drugs, says the deal will give Genentech rights to Seragon’s portfolio of oral drugs under development to treat certain kinds of breast cancer.



“Roche Buying Seragon In US For Up To $1.7 Billion” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.